Among them, the research on PD-L1 inhibitors in ovarian cancer, especially advanced ovarian cancer, recurrent ovarian cancer, and platinum-sensitive or platinum-resistant ovarian cancer, has been carried out successively (Mittica et al., 2016; Pujade-Lauraine et al., 2018; Zhang et al., 2022). This evidence concerns the gene CD274 and ovarian carcinoma.